We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Avantor (AVTR) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Avantor, Inc. (AVTR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Avantor, Inc. is a member of the Medical sector. This group includes 913 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Avantor, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AVTR's full-year earnings has moved 3.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AVTR has returned about 16.3% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 3.6% on a year-to-date basis. This means that Avantor, Inc. is outperforming the sector as a whole this year.
BrightSpring Health Services, Inc. (BTSG - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 58.9%.
Over the past three months, BrightSpring Health Services, Inc.'s consensus EPS estimate for the current year has increased 5.6%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Avantor, Inc. belongs to the Medical Services industry, which includes 72 individual stocks and currently sits at #91 in the Zacks Industry Rank. Stocks in this group have gained about 0% so far this year, so AVTR is performing better this group in terms of year-to-date returns. BrightSpring Health Services, Inc. is also part of the same industry.
Avantor, Inc. and BrightSpring Health Services, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Is Avantor (AVTR) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Avantor, Inc. (AVTR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Avantor, Inc. is a member of the Medical sector. This group includes 913 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Avantor, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AVTR's full-year earnings has moved 3.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AVTR has returned about 16.3% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 3.6% on a year-to-date basis. This means that Avantor, Inc. is outperforming the sector as a whole this year.
BrightSpring Health Services, Inc. (BTSG - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 58.9%.
Over the past three months, BrightSpring Health Services, Inc.'s consensus EPS estimate for the current year has increased 5.6%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Avantor, Inc. belongs to the Medical Services industry, which includes 72 individual stocks and currently sits at #91 in the Zacks Industry Rank. Stocks in this group have gained about 0% so far this year, so AVTR is performing better this group in terms of year-to-date returns. BrightSpring Health Services, Inc. is also part of the same industry.
Avantor, Inc. and BrightSpring Health Services, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.